UK FMD (foot and mouth disease) animal restrictions lifted but tissue technology industry awaits:
This article was originally published in Clinica
Executive Summary
At the time of going to press, Clinica was awaiting confirmation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) regarding possible changes to restrictions imposed on the trade of medical devices containing material sourced from biungulate animals, in light of the outbreaks of foot and mouth disease (FMD) in southern England earlier this month. Despite the early lifting of some restrictions on the movement and international trade of animals and products, an agency spokesperson could not confirm, on the eve of going to press, whether there had been any change to the situation, as set out in its August 14 notice (see Clinica No 1269, p 5).
You may also be interested in...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.